Galixir, founded in 2019, is dedicated to employing cutting-edge artificial intelligence (AI) technologies to accelerate drug research and development. By leveraging its AI algorithms and organically integrating computational chemistry and medicinal chemistry, Galixir optimizes preclinical R&D processes by providing high-quality drug candidates and cutting time and costs. This increases the overall probability of product launch. Collaborating with pharmaceutical companies and institutions globally, Galixir is advancing its drug discovery pipelines for multiple indications, and new drug candidates designed and screened by different modules of PyxirTM, the proprietary AIDD platform at Galixir, are proved to have high potency, surpassed the level of existing drugs while ensuring patentability.